Breast Cancer Clinical Trial

Droplet-BC Screening Test for the Detection of Breast Cancer, the DROPLET-BC Study

Summary

This study investigates if a new type of test called Droplet-BC screening test can classify breast cancer patients from non-cancer volunteers by circulating small-noncoding RNA in the blood with a statistical validity. This study also investigates if this test can classify the subgroup of breast cancer patients with a variety of conditions. Information from this study may provide a new method of breast cancer screening/diagnosis

View Full Description

Full Description

PRIMARY OBJECTIVE:

I. To determine the sensitivity and specificity of the Droplet-BC screening test for distinguishing breast cancer (BC) patients from non-cancer volunteers, using reference data confirmed at sites.

SECONDARY OBJECTIVES:

I. To determine the performance (sensitivity and specificity) of the Droplet-BC screening test for the classification of early-stage BC.

II. To determine the performance (sensitivity and specificity) of the Droplet-BC screening test for classifying patients into non-cancer volunteer (Breast Imaging-Reporting and Data System [BI-RADS] Categories 1 and 2) and BC patient subgroups.

III. To determine the performance (sensitivity and specificity) of the Droplet-BC screening test to classify different subgroups between non-cancer volunteers (BI-RADS category 1) versus BC patients plus non-cancer volunteers (BI- RADS category 2).

IV. To determine the performance (sensitivity and specificity) of the Droplet-BC screening test for the classification of non-cancer volunteers into BI-RADS categories 0-5 (small cohort study).

V. To determine the performance (sensitivity and specificity) of the Droplet-BC screening test for the multi-classification among cancer stage.

VI. To compare the sensitivity of the Droplet-BC test with mammogram for detecting BC by extracting a subgroup of BC patients that have mammogram results.

VII. To compare the sensitivity of the Droplet-BC test with ultrasound for detecting BC by extracting a subgroup of BC patients that have ultrasound results.

VIII. To compare the sensitivity of the Droplet-BC test with MRI for detecting BC by extracting a subgroup of BC patients that have magnetic resonance imaging (MRI) results.

IX. To conduct all analyses described above with subgroups of participants matched as closely as possible for age, race/ethnicity, cancer history, current medication, family history of cancer, and/or breast cancer gene (BRCA) status.

EXPLORATORY OBJECTIVES:

I. To evaluate the sensitivity and specificity of the Droplet-BC test to detect cancer among different age groups.

II. To evaluate the sensitivity and specificity of the Droplet-BC test to detect cancer among individuals of differing ethnicities.

III. To compare expression levels of small ribonucleic acid (RNAs) among different age groups.

IV. To compare expression levels of small RNAs among individuals of differing ethnicities.

OUTLINE:

Participants undergo collection of blood sample for the Droplet-BC test. Breast cancer patients' medical records are also reviewed.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

BREAST CANCER PATIENTS: Newly diagnosed with breast cancer
BREAST CANCER PATIENTS: Not received cancer treatment for newly diagnosed with breast cancer
BREAST CANCER PATIENTS: Able to comprehend, sign, and date the written informed consent document to participate in the study
BREAST CANCER PATIENTS: Able and willing to provide a one-time blood sample
BREAST CANCER PATIENTS: Age >= 18 years old
NON-CANCER VOLUNTEERS: Have undergone a screening mammogram
NON-CANCER VOLUNTEERS: Not currently taking any drugs for cancer treatment or any cancer prevention medication
NON-CANCER VOLUNTEERS: Able to comprehend, sign, and date the written informed consent document to participate in this study
NON-CANCER VOLUNTEERS: Able and willing to provide blood samples according to provided written instructions
NON-CANCER VOLUNTEERS: Seen by a provider (physician or advanced practice nurse [APN]) in the Cancer Prevention clinic at MD Anderson Cancer Center or other participating sites
NON-CANCER VOLUNTEERS: Age >= 18 years old

Exclusion Criteria:

BREAST CANCER PATIENTS: Known current pregnancy
BREAST CANCER PATIENTS: History of breast cancer treatment in the past
BREAST CANCER PATIENTS: Participation in any interventional clinical study within the previous 30 days in which an experimental treatment is administered or might be administered through a randomized assignment of the subject to one or more study groups
BREAST CANCER PATIENTS: Any condition that, in the opinion of the investigator, should preclude participation in the study
NON-CANCER VOLUNTEERS: Known current pregnancy
NON-CANCER VOLUNTEERS: History of breast cancer (breast ductal carcinoma in situ [DCIS] and invasive)
NON-CANCER VOLUNTEERS: History of any cancer except non-melanoma skin cancer and cervical dysplasia
NON-CANCER VOLUNTEERS: Participation in any interventional clinical study within the previous 30 days in which experimental treatment is administered or might be administered through a randomized assignment of the subject to one or more study groups
NON-CANCER VOLUNTEERS: Any condition that in the opinion of the investigator, should preclude participation in the study

Study is for people with:

Breast Cancer

Estimated Enrollment:

1200

Study ID:

NCT04671498

Recruitment Status:

Recruiting

Sponsor:

Preferred Medicine, Inc

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 3 Locations for this study

See Locations Near You

Northwestern University Feinberg School of Medicine
Chicago Illinois, 60611, United States More Info
Seema A Khan, MD
Contact
312-695-0990
Seema A Khan, MD
Principal Investigator
Roswell Park Comprehensive Cancer Center
Buffalo New York, 14263, United States More Info
Shipra Gandhi, MD
Contact
716-845-1285
Shipra Gandhi, MD
Principal Investigator
M D Anderson Cancer Center
Houston Texas, 77030, United States More Info
Naoto T. Ueno
Contact
713-792-2817
Naoto T. Ueno
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

1200

Study ID:

NCT04671498

Recruitment Status:

Recruiting

Sponsor:


Preferred Medicine, Inc

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider